OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $6.45 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ASPHF alerts:Sign Up Key Stats Today's Range$6.45▼$6.4550-Day Range$2.69▼$6.4552-Week Range$6.45▼$6.45VolumeN/AAverage Volume950 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAscentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. It also has APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449, an oral bioavailable inhibitor of FAK, ROS1, and ALK tyrosine kinases; APG-5918, an orally available and selective EED inhibitor; APG-265, a MDM2 protein degrade; and UBX1967/1325. In, addition it engages in medical research and development; venture capital investment; and rental services. The company has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address ASPHF Stock News HeadlinesAscentage Pharma’s Lisaftoclax Advances in Drug ApprovalNovember 17, 2024 | tipranks.comAscentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPANovember 17, 2024 | prnewswire.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 21, 2024 | Weiss Ratings (Ad)ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral ReportNovember 6, 2024 | prnewswire.comASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral ReportNovember 6, 2024 | prnewswire.comLive from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral PresentationSeptember 13, 2024 | prnewswire.comESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO CongressSeptember 8, 2024 | prnewswire.comAscentage Pharma Announces 2024 Interim ResultsAugust 22, 2024 | prnewswire.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $3.21 on January 1st, 2024. Since then, ASPHF stock has increased by 100.9% and is now trading at $6.45. View the best growth stocks for 2024 here. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASPHF CUSIPN/A CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.